BLAINJECTIONINJECTABLE
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BYOOVIZ (ranibizumab-nuna) by Samsung Bioepis is vascular endothelial growth factor inhibitors [moa]. Approved for neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion. First approved in 2021.
Drug data last refreshed 22h ago
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Worked on BYOOVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.